Thursday, June 1, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Associate Professor Emerita
Duke University
Durham, North Carolina
ONS Past President
Advanced Practice Registered Nurse
Department of Melanoma Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Professor
Deputy Chair, Department of Melanoma Medical Oncology
Co-Director, MD Anderson Brain Metastasis Clinic
Melanoma Medical Oncology, Investigational Cancer Therapeutics
The University of Texas
MD Anderson Cancer Center
Houston, Texas
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)
This activity is intended for oncology nurses, oncology nurse practitioners (NPs), and other members of the melanoma care team.
The goal of this activity is for learners to be better able to mitigate potential adverse events (AEs) associated with lymphocyte-activation gene 3 (LAG3) inhibitors as well as leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Associate Professor Emerita
Duke University
Durham, North Carolina
ONS Past President
Advanced Practice Registered Nurse
Department of Melanoma Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Professor
Deputy Chair, Department of Melanoma Medical Oncology
Co-Director, MD Anderson Brain Metastasis Clinic
Melanoma Medical Oncology, Investigational Cancer Therapeutics
The University of Texas
MD Anderson Cancer Center
Houston, Texas
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CE Released: 5/19/2023
Valid for credit through: 5/19/2024
processing....
The goal of this activity is for learners to be better able to mitigate potential AEs associated with LAG3 inhibitors as well as leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
